In a report released on February 14, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of $39.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Terence Flynn has given his Hold rating due to a combination of factors influencing Moderna’s current market position and future prospects. The company’s enterprise value is largely reflective of expected revenues, suggesting a stable support level. However, there are significant considerations regarding Moderna’s commercial execution, especially in competing against larger entities in key markets such as COVID and RSV. Another important factor is the execution of their development pipeline, with particular attention on the INT program with MRK and the CMV vaccine, which is a more immediate focus.
Moreover, Flynn considers Moderna’s financial projections and cost management strategies. The company has maintained its revenue guidance for 2025, but it is contingent on various factors such as approval timelines and market conditions. Additionally, the anticipated reduction in cash costs and the goal of achieving cash breakeven by 2028 are critical factors. These financial strategies are essential as they determine whether Moderna will need to raise additional equity. Due to these elements, Flynn’s Hold rating reflects a cautious stance while acknowledging potential for growth depending on future execution and market developments.
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Vertex Pharmaceuticals, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 6.0% and a 56.98% success rate on recommended stocks.